Last updated on November 2018

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients


Brief description of study

Itch, or pruritus, is the most common complain reported by patients with epidermolysis bullosa (EB) of all subtypes, and there is no current effective treatment. Itch often triggers scratching that creates new wounds and increases EB disease severity. This study aims to target the physiological mechanisms of pruritus. Substance P is a major mediator of pruritus and binds to the receptor neurokinin-1 (NK1), which is expressed in the central nervous system and the skin. VPD-737 (serlopitant), a drug that inhibits the NK1 receptor, has been shown to reduce severe itch in a previous study of 257 adult patients with chronic pruritus. The investigators are now testing VPD-737 in 14 patients with EB in a Phase II randomized, placebo-controlled, double-blinded clinical trial. Our goals is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in adolescents and adults with EB.

Clinical Study Identifier: NCT02654483

Contact Investigators or Research Sites near you

Start Over

Yana Dutt-Singkh

Stanford
Stanford, CA United States

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.